ClinicalTrials.gg
Active, not recruitingNCT06259409Updated Aug 27, 2026

Regenn® Therapy System Safety Study

A Phase 1 interventional study of Regenn® Negative Pressure Therapy System and Prevena™ Incision Management System in Surgical Wound, sponsored by Progenerative Medical, Inc. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Progenerative Medical, Inc · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 130 studies in Surgical Wound with a site in United States — 18 open to participants now, 22 under way, none of them phase 3. Surgical Wound · United States.

Planned enrollment
70th of 111
30 · median 50
Started
2024
with 5 others
Phase 1
5 of 130
1 open now
Primary completion
2026-12
later than 7 of 21 live
Registered
115th of 130
by date

Among the 130 studies in Surgical Wound with a site in United States, this one is the 70th largest by planned enrollment of the 111 interventional ones that give a count, is one of 6 that started in 2024, is one of 5 in phase 1, reaches primary completion later than 7 of the 21 other live ones, and was the 115th registered.

Surgical Wound

315 studies on the registry are indexed under Surgical Wound; 57 are open to participants now.

Browse Surgical Wound studies →

Open to participants now

18 of the 130 studies in Surgical Wound with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Surgical Wound studies recruiting now, 20 (59%) set no upper age limit and 10 (29%) stop at 75 or younger; 6 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies in Surgical Wound with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the safety of the investigational device, Regenn® Negative Pressure Therapy System (Regenn® Therapy), a form of Negative Pressure Wound Therapy (NPWT), in the post-operative surgical wounds of patients undergoing lumbar spinal fusion surgeries. The main questions the study aims to answer are:

  • The device-related serious adverse event rate.
  • Patient post-operative pain as assessed using a validated pain measurement scoring system.
  • The number and type of adverse events.
  • The rate of delayed seroma formation.

Participants will

  • Be screened for their suitability to participate in the investigational study using questions about their health, medical history, and current medications.
  • Undergo a physical exam, an assessment of patient vital signs and routine blood analyses.
  • Complete an Informed Consent Form if selected to participate in the investigational study.
  • Be randomly assigned to the different study arms.
  • Not change the operation of their respective device or to disturb components of their device.
  • Notify their surgeon or designated healthcare provider should they have any questions or encounter any issues with their device.
  • Attend two post-operative visits at approximately one month and three months.
03

Conditions studied

  • Surgical Wound

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria (must meet ALL):

  • Subject has provided written on a form reviewed and approved by the Institutional Review Board for the clinical site.
  • The subject is 18 - 80 years old.
  • The subject has Spondylolisthesis of Meyerding Grade II or less, or has Degenerative Disc Disease (DDD) accompanied by back pain with or without leg pain at a level between L1 and S1 confirmed by history and radiographic assessment. DDD is determined to be present if one or more of the following are noted:

    • Instability (defined as angulation ≥ 5 degrees and/or translation ≥ 3mm on flexion/extension radiographs;
    • Osteophyte formation of facet joints or vertebral endplates;
    • Decreased disc height, on average by >2mm, but dependent upon the spinal level;
    • Scarring / thickening of ligamentum flavum, annulus fibrosis, or facet joint capsule;
    • Herniated nucleus pulposus;
    • Facet joint degeneration / changes; and/or
    • Vacuum phenomenon.
  • Female subjects of must not be pregnant or nursing and must agree to use of for the study duration. Female subjects who are surgically sterile or are exempt from having a pregnancy test and birth control.
  • The subject is willing and able to comply with the protocol mandated follow-up visits and testing regimen.

Exclusion Criteria (candidates meeting ANY of the following at the time of the study procedure are NOT eligible):

  • Subject is unable or unwilling to provide informed consent or is unable to conform to the study protocol follow-up procedures and visits.
  • Subject has a (including allergic reaction) to antiplatelet/anticoagulant medications, nickel, titanium, bone allograft, or blood transfusion that is not amenable to pretreatment with or/and antihistamines.
  • Subject has a history of bleeding diatheses or coagulopathy.
  • Subject has concomitant hepatic insufficiency, thrombophlebitis, uremia, systemic lupus erythematosus (SLE), or any diseases.
  • Subject is receiving dialysis or therapy.
  • Subject suffered a hemorrhagic stroke \< 6 months prior to the study procedure.
  • Subject is undergoing spinal surgery for vertebral fracture, trauma, or scoliosis.
  • Subject has any form of active .
  • Subject is an intravenous drug user and/or alcoholic.
  • Subject is diagnosed with septicemia at the time of the study procedure.
  • Subject is a smoker.
  • Subject has Type I diabetes.
  • Subject has overt, uncontrolled Type II diabetes.
  • Subject has a condition requiring postoperative medications that would be expected to interfere with fusion (e.g., steroids), or has received drugs that interfere with bone metabolism within 2 weeks of the surgery.
  • Subject is suffering from gross obesity, defined as > 40% IBW.
  • Subject exhibits Waddell signs of Inorganic Behavior ≥ 3.
  • Subject has had a previous, anterior spinal fusion, interbody spinal fusion, or posterior spinal instrumentation at the involved level.
  • Subject has another medical condition, which may cause them to be non-compliant with the protocol, confound the data interpretation, or is associated with limited of less than two years.
  • Subject has a systemic disease of connective tissue such as Rheumatoid Arthritis, or Ankylosing Spondylitis.
  • Subject is a prisoner.
  • Subject is currently participating in an drug or another device study that has not completed the primary endpoint or that clinically interferes with the study endpoints. (Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials).
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Treatment Arm

    This group will receive the study device, Regenn® Negative Pressure Therapy System, a form of Negative Pressure Wound Therapy (NPWT). Regenn® Therapy manages the surgical wound by the application of reduced pressure therapy (i.e., mild vacuum). Reduced pressure therapy is controlled by a hand-sized, battery-operated pump and is delivered by an attached small, dressing that the surgeon places in the surgical wound at the end of the surgery. Reduced pressure therapy is applied while the patient recovers from surgery.

    Device: Regenn® Negative Pressure Therapy System

  • Active comparator
    Control Arm

    This group will receive the control device, also a form of Negative Pressure Wound Therapy (NPWT), which manages the surgical wound by the application of reduced pressure therapy (i.e., mild vacuum). Reduced pressure therapy is controlled by a hand-sized, battery-operated pump and is delivered by a small tube connected to a wound dressing placed over the closed surgical wound at the end of the surgery. Reduced pressure therapy is applied while the patient recovers from surgery.

    Device: Prevena™ Incision Management System

Interventions

  • DeviceRegenn® Negative Pressure Therapy System

    Controlled application of negative pressure (i.e., reduced atmospheric pressure or mild vacuum) to manage the wound environment.

    Also known as: NPWT, Negative Pressure Wound Therapy

  • DevicePrevena™ Incision Management System

    Controlled application of negative pressure (i.e., reduced atmospheric pressure or mild vacuum) to manage the wound environment.

    Also known as: NPWT, Negative Pressure Wound Therapy

06

What researchers measure

Primary outcomes

  1. Device-related Serious Adverse Event Rate

    The device-related serious adverse event rate associated with the use of the investigational device and the comparator device. Wound complications requiring surgical intervention, such as wound dehiscence, will be the primary indicator of blood supply at the wound site, damage to the surrounding tissue, and progression of wound healing.

    Time frame: Post-operative follow ups at 2-8 weeks and 3-6 months.

Secondary outcomes

  1. Post-operative Pain Profile

    Post-operative pain will be assessed using the Numerical Rating Scale (NRS), a validated pain measurement scoring system with a pain rating scale of 0 - 10, where zero means "No pain" and 10 means "The worst pain imaginable"

    Time frame: Post-operative up to the 3-6 month follow up visit.

  2. Adverse Events Related to the Investigational Device

    The number and type of adverse events associated with the use of the investigational device. Assessment will include wound complications not requiring surgical intervention, device complications, medical complications and infections complications.

    Time frame: Post-operative follow ups at approximately one month and three months.

Other outcomes

  1. Delayed Seroma Formation Rate

    Delayed seroma formation will be assessed by ultrasound imaging during post-operative follow up visits.

    Time frame: Post-operative follow up at 2-8 weeks (at the surgeon's discretion) and at 3-6 months (required).

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2024
First posted
Feb 14, 2024
StartActual
Oct 9, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06259409
Lead sponsor
Progenerative Medical, Inc
Responsible party
Sponsor
First posted
Feb 14, 2024
Start date
Oct 9, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Aug 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion